At a glance
ClinicalIndex Comparison RecordN/ACompleted· 444 enrolled
Drug / intervention
Dilapan-Sdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
International Observational E-Registry on the Use of Dilapan-S / Dilasoft Osmotic Dilators for Cervical Ripening Prior to Labour Induction
In Brief
An observational study evaluating Dilapan-S for Labour Onset and Length Abnormalities and Labor; Forced or Induced, Affecting Fetus or Newborn. Completed, enrolled 444 participants across 11 sites in 7 countries.
Detailed Summary
International Observational E-Registry on the use of DILAPAN-S® osmotic dilator / DILASOFT® osmotic dilator for cervical ripening prior to labour induction.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLabour Onset and Length Abnormalities, Labor; Forced or Induced, Affecting Fetus or Newborn
CountriesCzechia, Germany, India, Russia, Slovakia, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartMay 2015
Primary CompletionDec 2016
TodayJul 2026
First PostedDec 17, 2014
Enrollment StartMay 1, 2015
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.5 years ago
Interventions
Dilapan-Sdevice
Synthetic osmotic dilators Dilapan-S, Dilasoft for cervical ripening prior to induction of labor in women with unfavourable cervix